Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib +/- TSR-042 in Recurrent Endometrial Cancer
NCT03016338Phase 2Active, not recruiting
- Sponsor
- University Health Network
- Start
- Nov 2017
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, dostarlimab in endometrial cancer (EC), sponsored by University Health Network. Started Nov 2017; status: active, not recruiting.
02
Drugs
niraparibdostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03016338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03016338.